Brii Biosciences Ltd
2137.HK- Latest Trade
- trading lower8.46HKD
- Change
- -0.3
- % Change
3.42%Negative
- Day Range
- 8.36 - 8.82
- 52-Week Range
- 7.15 - 52.60
As of Jul 1 2022. Values delayed up to 15 minutes
- Previous Close
- 8.76
- Open
- 8.72
- Volume
- 5,887,364.00
- 3 Month Average Trading Volume
- 120.36
- Shares Out (Mil)
- 722.27
- Market Cap
- 6,113.19
- Forward P/E
- -37.11
- Dividend Yield
- -99,999.99
Key Statistics
1.75 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 1.56
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.65
- Long Term Debt/Equity (Quarterly)
- 0.38
- Return On Investment (TTM)
- -99,999.99
- Return On Equity (TTM)
- -99,999.99
2021 (millions USD)
About Brii Biosciences Ltd
Company Information
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Executive Leadership
- Zhi Hong
- Executive Chairman of the Board and Chief Executive Officer
- Yongqing Luo
- President, General Manager of Greater China, Executive Director
- Ankang Li
- Chief Financial Officer, Joint Company Secretary
- Lisa Trivison Beck
- Senior Vice President (Business Development and Portfolio Strategy)
- Jean-luc Samuel Francois Girardet
- Senior Vice President (Head of Pharmaceutical Sciences)
- Lianhong Xu
- Senior Vice President (Head of Medicinal Chemistry)
- Qing Zhu
- Senior Vice President (head of biopharmaceutical research)
- Li Yan
- Chief Medical Officer
- Wing Tsz Ho
- Joint Company Secretary
- Axel Bouchon
- Non-Executive Director
- Robert T. Nelsen
- Non-Executive Director
- Gregg Huber Alton
- Non-Executive Independent Director
- Martin J. Murphy
- Non-Executive Independent Director
- Hui Tang
- Non-Executive Independent Director
- Yiu Wa Tsui
- Non-Executive Independent Director
Latest News
- BusinessChina Junshi's potential COVID drug shows promise in small trial
An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients, according to a small clinical trial.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,806.10 | 0.11%Positive |
| Copper | 679.40 | 2.12%Negative |
| Brent Crude Oil | 111.63 | -- |
| CBOT Soybeans | 1,622.00 | 3.16%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | 1.06%Positive |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes